347 related articles for article (PubMed ID: 21813065)
1. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.
Greisen SR; Moller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Jørgensen A; Hvid M; Deleuran B
Clin Exp Rheumatol; 2011; 29(4):689-92. PubMed ID: 21813065
[TBL] [Abstract][Full Text] [Related]
2. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
[TBL] [Abstract][Full Text] [Related]
3. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
4. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.
Greisen SR; Rasmussen TK; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Hvid M; Deleuran B
Scand J Rheumatol; 2014; 43(2):101-8. PubMed ID: 24182347
[TBL] [Abstract][Full Text] [Related]
5. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
6. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
7. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
8. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
11. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
[TBL] [Abstract][Full Text] [Related]
12. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
14. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis.
Heftdal LD; Loft AG; Hendricks O; Ashouri Christiansen A; Schiøttz-Christensen B; Arnbak B; Jurik AG; Østgård R; Winding Deleuran B; Møller HJ; Greisen SR
Scand J Clin Lab Invest; 2018 Oct; 78(6):483-489. PubMed ID: 30176763
[TBL] [Abstract][Full Text] [Related]
15. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
16. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis.
Aristoteli LP; Møller HJ; Bailey B; Moestrup SK; Kritharides L
Atherosclerosis; 2006 Feb; 184(2):342-7. PubMed ID: 15979079
[TBL] [Abstract][Full Text] [Related]
17. Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Axelsson J; Møller HJ; Witasp A; Qureshi AR; Carrero JJ; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Moestrup SK; Stenvinkel P
Am J Kidney Dis; 2006 Dec; 48(6):916-25. PubMed ID: 17162146
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis.
Jude C; Dejica D; Samasca G; Balacescu L; Balacescu O
Rheumatol Int; 2013 Apr; 33(4):1031-7. PubMed ID: 23011084
[TBL] [Abstract][Full Text] [Related]
19. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
Møller HJ; Moestrup SK; Weis N; Wejse C; Nielsen H; Pedersen SS; Attermann J; Nexø E; Kronborg G
Crit Care Med; 2006 Oct; 34(10):2561-6. PubMed ID: 16915112
[TBL] [Abstract][Full Text] [Related]
20. Evidence for M2 macrophage activation in patients with enthesitis-related arthritis category of juvenile idiopathic arthritis.
Bhattacharya S; Yadav A; Aggarwal A
Clin Rheumatol; 2019 Jun; 38(6):1715-1719. PubMed ID: 30734215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
